Warburg Pincus has acquired Sebia, a global specialty In Vitro Diagnostic (IVD) leader headquartered in Lisses, France, for an undisclosed amount. This transaction marks a significant corporate acquisition, bringing Sebia under new ownership to support its continued growth and innovation in the diagnostic sector.
Founded in 1967, Sebia specializes in the screening and monitoring of various diseases, primarily in areas such as Oncology, including Multiple Myeloma, Diabetes, Hemoglobinopathy, Autoimmunity, and other rare pathologies. The company's mission is to provide powerful tools that translate what is happening in a patient's body into a readable and interpretable language, which it refers to as its "new language of life." Sebia maintains high standards in continuous technological advances, scientific excellence, and manufacturing capabilities, offering a robust pipeline of new tests and automated equipment leveraging technologies like Capillary Electrophoresis and Gel Electrophoresis.
The acquisition by Warburg Pincus is strategic, aiming to capitalize on Sebia's established leadership, extensive global presence across more than 120 countries with over 20,000 installed instruments, and its team of over 1,300 employees. This move is expected to support Sebia's commitment to innovation and expansion of its diagnostic solutions portfolio, further strengthening its capabilities in advanced diagnostics and market reach. The firm’s investment underscores the value seen in Sebia’s strong market position and its potential for continued development of critical diagnostic tools.
Looking ahead, the combined entity is positioned to enhance its footprint in the global IVD market. The acquisition is anticipated to accelerate Sebia's mission of providing cutting-edge diagnostic solutions, driving advancements in patient care and contributing to improved health outcomes worldwide.